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Uremic pruritus is a common problem in patients with end-stage renal disease 
(ESRD), but the underlying mechanisms are not yet fully understood. We aimed 
to investigate the association between severity of uremic pruritus and cutaneous 
serine protease activity, as well as proteinase-activated receptor-2 (PAR-2) ex- 
pression. Twelve ESRD patients with pruritus, 4 ESRD patients without pruritus, 
and 6 healthy controls were enrolled. Skin biopsies were obtained from the 
abdomen. Protease activity and PAR-2 expression in the epidermis were exam-
ined by in situ zymography and confocal laser microscopy, respectively. All 
ESRD patients presented more pronounced cutaneous protease activity com-
pared with that in healthy controls. The skin samples from the patients with 
pruritus showed higher protease activity than either nonpruritic ESRD patients 
or healthy controls. The epidermis in all samples of ESRD patients presented 
higher immunoreactivity against PAR-2 versus those of healthy controls. In ad-
dition, correlation analysis between PAR-2 expression and VAS pruritus scores 
showed a significant positive correlation. Our data suggests that levels of serine 
protease and PAR-2 expression could play important roles in the pathogenesis 
of uremic pruritus.
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Introduction
Uremic pruritus is a common and burdensome prob-
lem affecting up to 86% of patients with end-stage renal 
disease (ESRD)1-3). Although the underlying mechanisms 
are not yet fully understood, many causative factors have 
been suggested1-5). These include uremic xerosis, secon-
dary hyperparathyroidism, calcium phosphate crystals, 
uremic neuropathy, and iron-deficiency anemia4). In addi-
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tion, immune system abnormalities or changes in the opioi- 
dergic system have been proposed to explain the patho-
physiology of uremic pruritus5). Histamine, which is a 
common mediator of various cutaneous disorders asso-
ciated with an itching sensation, also plays a pathogenic 
role in some patients with uremic pruritus. However, be-
cause many of these patients are refractory to treatment 
with antihistamines, there must be additional histamine- 
independent mediators that need to be identified.
Proteinase-activated receptors (PARs) are G-protein-cou- 
pled receptors that are activated by certain proteinases6,7). 
Among the PARs, PAR-2 is cleaved by trypsin-like serine 
proteases and is associated with acute inflammation7). In 
addition, PAR-2 in spinal apparent neurons has been 
shown to have an important role in hyperalgesia through 
its effects on the pain pathway7). Furthermore, recent in-
vestigations have suggested that PAR-2 is one of the hista-
mine-independent mediators of itching6,8). Steinhoff et 
al.6) demonstrated that significantly enhanced PAR-2 sig-
naling was found in patients with atopic dermatitis, and 
intradermal injection of PAR-2 agonists induced enhanced 
and prolonged scratching response. This suggests a role 
of PAR-2 in the sensation of pruritus. However, neither 
the status of epidermal PAR-2 expression nor the relation-
ship between PAR-2 and uremic pruritus in ESRD patients, 
have been studied. In this study, we investigated cutaneous 
PAR-2 expression and serine protease activity in ESRD 
patients with pruritus using confocal laser microscopy and 
in situ zymography, and these were compared to those 
of healthy controls and nonpruritic ESRD patients.
MATERIALS AND METHODS
1. Patients
There were 12 ESRD patients with pruritus, 4 non-
pruritic ESRD patients, and 6 healthy controls who were 
enrolled in this study. The study was approved by the 
Institutional Review Board of Yonsei University College 
of Medicine, and informed consent was obtained from 
all participants. The ESRD status was defined as an esti-
mated glomerular filtration rate lower than 15 mL/min/ 
1.73 m2, as calculated by the Modification of Diet in 
Renal Disease equation. No participants had a prior his-
tory of any dermatologic disease other than pruritus. Medi- 
cations related  to pruritus except anti-histamine were dis-
continued at least two weeks before starting the baseline 
evaluation. At baseline, visual analog scale (VAS) and pru-
ritus grading score for assessing severity of pruritus were 
recorded4).
2. Epidermal serine protease activity
Skin biopsy specimens from all participants were ob-
tained from a similar area of the abdomen without remar- 
kable excoriations or crusts. Serine protease activity in 
the epidermis of 5-μm-thick frozen sections were examined 
by in situ zymography using the EnzCheck® Protease assay 
kit (Invitrogen Inc.; Grand Island, NY, USA) as previously 
described9).
3. Confocal laser microscopic study
Epidermal PAR-2 expression in biopsy material was 
visualized by immunofluorescence study. Briefly, paraf-
fin-embedded samples were cut into 4-μm-thick sections 
and deparaffinized. The deparaffinized sections were in-
cubated for 2 hours at room temperature with a 1:250 
dilution of a rabbit anti-human PAR-2 polyclonal anti-
body (Santa Cruz Biotechnology, Inc.; Santa Cruz, CA, 
USA) in blocking buffer (1% w/v BSA and 0.1% w/v cold- 
water fish gelatin in PBS). The sections were washed with 
PBS and then incubated for 1 hour at room temperature 
with a 1:100 dilution of fluorescein isothiocyanate-labeled 
goat anti-rabbit IgG antibody (Santa Cruz Biotechnology, 
Inc.) in blocking buffer. Stained tissue sections were washed 
with PBS and then examined with a C1 Plus confocal 
laser microscope (Nikon; Tokyo, Japan). Fluorescence in-
tensities were analyzed using Metamorph software version 
7.7.1.0 (Molecular Devices Inc.; Sunnyvale, CA, USA).
4. Statistical analysis
Statistical analyses were performed by the nonparame- 
tric Kruskal-Wallis test for multiple comparisons. Signifi- 
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Table 1. Baseline characteristics of study participants
 Healthy control individuals Nonpruritic ESRD patients Uremic pruritus patients
Number of patients (male/female)  6 (2/4)  4 (3/1) 12 (9/3)
Median age in yr (range) 67 (45-75) 58 (49-66) 66 (41-79)
Time on dialysis (months) N.A 28±17 31±12
Diabetes mellitus (n)  0  3  8
VAS*  0  0  5.25 (2-10)
Pruritus grading score*  0  0  8.5 (6-18)
*Scores are expressed as median values (range from minimum-maximum). ESRD, end-stage renal disease; N.A, not applicable; 
VAS, visual analog scale.
Fig. 1. Computer-based fluorescence intensity analyses. Com- 
parison of serine protease activity was done in healthy controls 
(n=6), nonpruritic ESRD patients (n=4), and uremic pruritus 
patients (n=12). *p<0.01, **p< 0.001.
cant differences obtained by Kruskal-Wallis analysis were 
confirmed by Mann-Whitney U test. The relationship be-
tween PAR-2 expression and VAS pruritus scores was as-
sessed by spearman’s correlation analysis. All analyses 
were performed using SAS software version 9.2 (SAS Insti- 
tute Inc., Cary, NC, USA) and p-values of <0.05 were 
considered to be significant.
RESULTS
1. Patients characteristics
Baseline characteristics of the participants are summa- 
rized in Table 1. The median age of ESRD patients with 
pruritus was 66 years (ranges from 41 to 79), and male 
gender was 75%. The median VAS and pruritus score were 
5.25 (ranges from 1 to 10). The median age and gender 
ratio of ESRD patients without pruritus and healthy con-
trol were comparable with ESRD patients with pruritus.
2. Epidermal serine protease activity
All ESRD patients without pruritus presented more 
pronounced cutaneous protease activity by computer- 
based analysis of relative fluorescence intensities, com-
pared with that in healthy controls (Fig. 1, p<0.01). In 
addition, the skin samples obtained from uremic pruritus 
patients showed higher protease activity than either non-
pruritic ESRD patients or healthy controls (p<0.001). 
3. Confocal laser microscopic study of epidermal 
PAR-2 expression
Regardless of pruritus status, the epidermis in all sam-
ples of ESRD patients presented higher immunoreactivity 
against PAR-2 versus those of healthy controls (Fig. 2). 
Computer-based fluorescence intensity analysis revealed 
that significantly higher PAR-2 expression relative to 
healthy controls were found in samples from nonpruritic 
(p<0.01) and pruritic ESRD patients (p<0.001). Some- 
what higher PAR-2 expression were found in samples from 
pruritic versus nonpruritic ESRD patients, but the diffe- 
rence was not statistically significant. However, PAR-2 
expression in the upper half of epidermal layers of skin 
were significantly higher in samples from pruritic versus 
nonpruritic ESRD patients (p<0.001) (Fig. 2D).
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Fig. 2. Confocal laser microscopic study of epidermal PAR-2 expression. The skin samples obtained from (A) healthy controls, (B)
nonpruritic ESRD patients, and (C) uremic pruritus patients indicate there was higher PAR-2 expression in uremic pruritus patients
than in healthy controls or nonpruritic ESRD patients (original magnification ×400, Bars=100 μm). (D) Computer-based relative 
fluorescence intensity analyses of PAR-2 expression in the entire epidermis and the upper half of epidermis were done in healthy
controls (n=6), nonpruritic ESRD patients (n=4), and uremic pruritus patients (n=12). *p<0.01, **p<0.001.
Interestingly, correlation analysis between PAR-2 ex-
pression and VAS pruritus scores in ESRD patients showed 
a significant positive correlation (Spearman’s rho=0.670; 
p=0.005) (Fig. 3).
DISCUSSION
The PAR proteins are G-protein coupled receptors cha- 
racterized by self-activation following specific proteolytic 
cleavage of their extracellular domains10). Among the four 
identified PAR members, PAR-2 is activated by trypsin-like 
serine proteases; whereas, the others are activated by 
thrombin11). In skin, PAR-2 is abundantly expressed and is 
known to be a sensor for endogenous and exogenous pro- 
teases, and to play numerous pathophysiological roles11,12). 
In atopic dermatitis, PAR-2 in the skin is markedly expre- 
ssed on primary afferent nerve fibers and significantly 
related to pruritus6). Provocation of an itching sensation 
by intracutaneous injection of endogenous PAR-2 agonists 
has suggested that this receptor is one of the histamine-in-
dependent pruritic mediators, and that PAR-2 might be 
a new therapeutic target for treatment of itching in atopic 
dermatitis6).
Uremic pruritus is a common complication in ESRD 
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Fig. 3. The correlation analysis between epidermal proteinase- 
activated receptor-2 expression and visual analogue scale of pruri-
tus. Correlation analysis showed a significant positive correlation
(spearman's rho=0.670; p=0.005).
patients3). Various treatment modalities, such as photothe- 
rapy, i.e., with broad-band ultraviolet B and narrow-band 
ultraviolet B, and oral medications, including antihist-
amines, gabapentin, gamma linolenic acid, or kappa-opioid 
receptor antagonist, have been used for the treatment of 
uremic pruritus with various treatment outcomes4,13,14). 
In this study, we have investigated the association be-
tween the severity of pruritus in ESRD patients and levels 
of cutaneous serine protease activity, as well as PAR-2 
expression. From the results, we hypothesized that uremic 
pruritus might be related to PAR-2 expression, as in atopic 
dermatitis. Our data revealed that epidermal PAR-2 expre- 
ssion was significantly increased in ESRD patients com-
pared to healthy controls. In addition, in situ zymography 
confirmed that protease activity was upregulated in uremic 
skin. Pruritic ESRD patients showed significantly higher 
levels of PAR-2 expressed in the skin, especially in the 
upper epidermis, than that in ESRD patients without 
pruritus. Previous studies have demonstrated that ESRD 
patients presented increased serum trypsin levels and de-
creased trypsin inhibitory capacity15,16). In addition, the 
protein-energy wasting, which is commonly found in 
ESRD patients, is attributable to increased levels of specific 
proteolytic activities, including activation of caspase-3 
and the ubiquitin-proteosome system17). We suggest that 
the pathological milieu in uremic skin might increase pro-
teolytic activity that results in the increased PAR-2 expre- 
ssion in the skin of ESRD patients, and that this mecha-
nism provokes pruritus in such patients.
There are several limitations in this study. First, various 
etiologic factors associated with uremic pruritus were not 
fully investigated. Biochemical parameters such as hemo-
globin, serum calcium, phosphorous, ferritin, vitamin D, 
and intact-parathyroid hormone were not measured. 
Second, the basic investigation about the pathogenesis of 
how uremia induces PAR-2 expression was not per- 
formed. Inflammatory cytokines that might increase pro-
tease activities should have been done. Lastly, the number 
of patients enrolled in this study were very small. How- 
ever, this is a pilot study so that further evaluations in-
cluding basic research for pruritus pathway and large 
scaled clinical trials will be conducted.
In this report, we have demonstrated that protease acti- 
vity and PAR-2 expression in the epidermis were signi- 
ficantly increased in uremic pruritus patients compared 
with nonpruritic ESRD patients and healthy controls. In 
addition, PAR-2 expression and VAS pruritus scores in 
ESRD patients showed a significant correlation. Although 
the exact pathogenesis of uremia-induced cutaneous 
PAR-2 expression remains to be more fully explained, 
our data does suggest that serine proteases and PAR-2 
in the skin could have an important function in the patho-
genesis of uremic pruritus.
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